64706-54-3 Usage
Uses
Bepridil is protective against Ebola virus. Bepridil is used in biological study of shortening of electromechnical window in ketamine/xylazine-anesthetized guinea pig model improved QTc interval prolongation and assessed pro-arrhythmic risk during early drug development. Bepridil is also used in therapeutic use in novel high/low solubility classification methods for new molecular entities.
Definition
ChEBI: A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Enzyme inhibitor
This substituted pyrrolidine (FWfree-base = 366.55 g/mol) is a calcium channel blocker that inhibits the Na+ /Ca2+ exchange, exhibiting antiarrhythmic, antianginal, and vasodilatory properties. Bepridil inhibits the growth of certain brain tumors in vitro. Bepridil also binds to troponin C. Target(s): Ca2+ channels; ATP-sensitive K+ channels; Na+ -activated K+ channels.
Check Digit Verification of cas no
The CAS Registry Mumber 64706-54-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,4,7,0 and 6 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 64706-54:
(7*6)+(6*4)+(5*7)+(4*0)+(3*6)+(2*5)+(1*4)=133
133 % 10 = 3
So 64706-54-3 is a valid CAS Registry Number.
InChI:InChI=1/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
64706-54-3Relevant articles and documents
THERAPY FOR COMPLICATIONS OF DIABETES
-
, (2009/07/02)
A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.
